- Home
- DCBO vs TVTX Comparison
DCBO vs TVTX Comparison
Compare DCBO & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCBO
- TVTX
- Stock Information
- Founded
- DCBO 2016
- TVTX 2008
- Country
- DCBO Canada
- TVTX United States
- Employees
- DCBO N/A
- TVTX N/A
- Industry
- DCBO
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- DCBO
- TVTX Health Care
- Exchange
- DCBO Nasdaq
- TVTX Nasdaq
- Market Cap
- DCBO 1.3B
- TVTX 1.3B
- IPO Year
- DCBO 2020
- TVTX N/A
- Fundamental
- Price
- DCBO $46.83
- TVTX $17.72
- Analyst Decision
- DCBO Strong Buy
- TVTX Buy
- Analyst Count
- DCBO 7
- TVTX 13
- Target Price
- DCBO $54.71
- TVTX $23.46
- AVG Volume (30 Days)
- DCBO 74.2K
- TVTX 1.4M
- Earning Date
- DCBO 11-08-2024
- TVTX 10-31-2024
- Dividend Yield
- DCBO N/A
- TVTX N/A
- EPS Growth
- DCBO 1403.35
- TVTX N/A
- EPS
- DCBO 0.56
- TVTX N/A
- Revenue
- DCBO $209,170,000.00
- TVTX $203,447,000.00
- Revenue This Year
- DCBO $20.98
- TVTX $62.45
- Revenue Next Year
- DCBO $15.49
- TVTX $59.30
- P/E Ratio
- DCBO $78.41
- TVTX N/A
- Revenue Growth
- DCBO 22.67
- TVTX 57.08
- 52 Week Low
- DCBO $33.81
- TVTX $5.12
- 52 Week High
- DCBO $56.41
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- DCBO 47.11
- TVTX 51.53
- Support Level
- DCBO $44.94
- TVTX $16.89
- Resistance Level
- DCBO $51.19
- TVTX $19.51
- Average True Range (ATR)
- DCBO 1.64
- TVTX 1.23
- MACD
- DCBO -0.24
- TVTX -0.16
- Stochastic Oscillator
- DCBO 21.19
- TVTX 26.69
About DCBO Docebo Inc.
Docebo Inc is a provider of cloud-based learning management systems.. The solutions provided by the company are sold on a subscription model and subscriptions are typically structured with an initial fixed term of between one and three years, without the ability for customers to terminate for convenience. The company charges its customers based on a per-learner, per-module basis, varying depending on the size of the organization and complexity. The majority of the revenue is derived from customers based in North America.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.